FLOT-话题@MedSci

#FLOT#

5篇内容 | 676人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2185302, encodeId=3f2a218530267, content=<a href='/topic/show?id=1e66e509f7' target=_blank style='color:#2F92EE;'>#FLOT#</a> <a href='/topic/show?id=7b2910612398' target=_blank style='color:#2F92EE;'>#度伐利尤单抗#</a> <a href='/topic/show?id=41a7110e7258' target=_blank style='color:#2F92EE;'>#ASCO GI#</a> <a href='/topic/show?id=bbbc110e7392' target=_blank style='color:#2F92EE;'>#MATTERHORN#</a>, objectTitle=2024 ASCO GI | MATTERHORN研究结果公布，围术期D+FLOT方案提高12% pCR率, objectType=article, longId=811846, objectId=ad7081184621, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-examining-medical-report-PJUYHWX.jpg, objectUrl=/article/show_article.do?id=ad7081184621, replyNumber=0, likeNumber=22, createdTime=2024-02-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=ad7081184621, moduleTitle=2024 ASCO GI | MATTERHORN研究结果公布，围术期D+FLOT方案提高12% pCR率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad7081184621)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1985163, encodeId=7aa71985163e5, content=<a href='/topic/show?id=1e66e509f7' target=_blank style='color:#2F92EE;'>#FLOT#</a>, objectTitle=Nat Commun：Ⅱ期随机临床试验: 局部晚期胃癌患者新辅助FLOT与SOX疗法较量, objectType=article, longId=203999, objectId=4c6120399925, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c6120399925, replyNumber=0, likeNumber=42, createdTime=2021-02-03, rootId=0, userName=zjshifan_98647306, userId=99cf2500102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c6120399925, moduleTitle=Nat Commun：Ⅱ期随机临床试验: 局部晚期胃癌患者新辅助FLOT与SOX疗法较量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c6120399925)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985164, encodeId=28671985164c5, content=<a href='/topic/show?id=1e66e509f7' target=_blank style='color:#2F92EE;'>#FLOT#</a>, objectTitle=Blood：Flotetuzumab作为难治性AML患者的补救免疫疗法的疗效和安全性, objectType=article, longId=207128, objectId=b43f20e12849, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b43f20e12849, replyNumber=0, likeNumber=50, createdTime=2021-11-15, rootId=0, userName=zjshifan_98647306, userId=99cf2500102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b43f20e12849, moduleTitle=Blood：Flotetuzumab作为难治性AML患者的补救免疫疗法的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b43f20e12849)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985162, encodeId=e66b1985162b3, content=<a href='/topic/show?id=1e66e509f7' target=_blank style='color:#2F92EE;'>#FLOT#</a>, objectTitle=Blood：Floteuzumab挽救治疗免疫治疗难治性急性髓系白血病, objectType=article, longId=202251, objectId=2ea82022518b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ea82022518b, replyNumber=0, likeNumber=34, createdTime=2021-05-26, rootId=0, userName=zjshifan_98647306, userId=99cf2500102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ea82022518b, moduleTitle=Blood：Floteuzumab挽救治疗免疫治疗难治性急性髓系白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ea82022518b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985160, encodeId=e290198516018, content=<a href='/topic/show?id=1e66e509f7' target=_blank style='color:#2F92EE;'>#FLOT#</a>, objectTitle=Lancet：多西紫杉醇3D疗法（FLOT）治疗晚期可切除胃癌, objectType=article, longId=164240, objectId=143d164240fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=143d164240fb, replyNumber=0, likeNumber=29, createdTime=2020-01-03, rootId=0, userName=zjshifan_98647306, userId=99cf2500102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=143d164240fb, moduleTitle=Lancet：多西紫杉醇3D疗法（FLOT）治疗晚期可切除胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=143d164240fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985161, encodeId=72541985161a8, content=<a href='/topic/show?id=1e66e509f7' target=_blank style='color:#2F92EE;'>#FLOT#</a>, objectTitle=LANCET ONCOL:《柳叶刀》子刊公布FLOT4总生存结果：局部晚期胃或胃食管交界部腺癌围术期化疗FLOT优于ECF/ECX, objectType=article, longId=164686, objectId=6f471646868d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f471646868d, replyNumber=0, likeNumber=34, createdTime=2020-02-18, rootId=0, userName=zjshifan_98647306, userId=99cf2500102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f471646868d, moduleTitle=LANCET ONCOL:《柳叶刀》子刊公布FLOT4总生存结果：局部晚期胃或胃食管交界部腺癌围术期化疗FLOT优于ECF/ECX, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f471646868d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FLOT

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#FLOT# #度伐利尤单抗# #ASCO GI# #MATTERHORN#

2024 ASCO GI | MATTERHORN研究结果公布，围术期D+FLOT方案提高12% pCR率

2024-02-01发表于陕西省

zjshifan_98647306 (审核中...)

前往app查看评论内容

#FLOT#

Nat Commun：Ⅱ期随机临床试验: 局部晚期胃癌患者新辅助FLOT与SOX疗法较量

2021-02-03

zjshifan_98647306 (审核中...)

前往app查看评论内容

#FLOT#

Blood：Flotetuzumab作为难治性AML患者的补救免疫疗法的疗效和安全性

2021-11-15

zjshifan_98647306 (审核中...)

前往app查看评论内容

#FLOT#

Blood：Floteuzumab挽救治疗免疫治疗难治性急性髓系白血病

2021-05-26

zjshifan_98647306 (审核中...)

前往app查看评论内容

#FLOT#

Lancet：多西紫杉醇3D疗法（FLOT）治疗晚期可切除胃癌

2020-01-03

zjshifan_98647306 (审核中...)

前往app查看评论内容

#FLOT#

LANCET ONCOL:《柳叶刀》子刊公布FLOT4总生存结果：局部晚期胃或胃食管交界部腺癌围术期化疗FLOT优于ECF/ECX

2020-02-18

科室
- - 订阅+
  - 更多科室
工具
服务